Testing new treatments for people with IgG4 related disease (fibro-inflammatory condition).
- Dr Daman Langguth
Clinical Trial Coordinator
- Venita Bali
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in Immunoglobulin G4-related disease (IgG4) Related Disease (MITIGATE)
About this research project
There are currently no medicinal products approved for the treatment of IgG4-RD. The majority of cases follow a relapsing course that can lead to permanent tissue damage with potential morbidity and mortality. This project aims to develop an effective product.
The purpose of this study is to better understand the safety and side effects of Inebilizumab and to find out if it helps people with IgG4 related disease.